Literature DB >> 21660063

DNA triplex-mediated inhibition of MET leads to cell death and tumor regression in hepatoma.

G Singhal1, M Z Akhter, D F Stern, S D Gupta, A Ahuja, U Sharma, N R Jagannathan, M R Rajeswari.   

Abstract

Mesenchymal epithelial transition factor (MET) is one of the critical cell signaling molecules whose aberrant expression is reported in several human cancers. The aim of the study is to investigate the antigene and antiproliferative effect of short triplex forming oligonucleotides, TFO-1 (part of the positive regulatory element) and TFO-2 (away from the transcription start site) on MET expression. HepG2 cells transfected only with TFO-1 (but not with TFO-2 and non-specific TFO) significantly decreased MET levels, which is accompanied by decrease in antiapoptotic proteins and increase in pro-apoptotic proteins. Phosphoproteome-array analysis of 46 intracellular kinases revealed hypophosphorylation of about 15 kinases including ERK, AKT, Src and MEK, suggesting the growth inhibitory effect of TFO-1. Further, the efficacy of TFO-1 was tested on diethylnitrosamine-induced liver tumors in wistar rats. T2-weighted magnetic resonance imaging showed decrease in liver tumor volume up to 90% after treatment with TFO-1. Decreased MET expression and elevated apoptotic activity further indicate that TFO-1 targeted to c-met leads to cell death and tumor regression in hepatoma. Formation of stable DNA triplex between TFO-1 and targeted gene sequence was confirmed by circular dichroic spectroscopy and gel retardation assay. Therefore, it can be concluded that DNA triplex-based therapeutic approaches hold promise in the treatment of malignancies associated with MET overexpression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21660063      PMCID: PMC4856167          DOI: 10.1038/cgt.2011.21

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  42 in total

1.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

Authors:  L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

2.  Molecular cloning of a new transforming gene from a chemically transformed human cell line.

Authors:  C S Cooper; M Park; D G Blair; M A Tainsky; K Huebner; C M Croce; G F Vande Woude
Journal:  Nature       Date:  1984 Sep 6-11       Impact factor: 49.962

3.  Antigene and antiproliferative effects of a c-myc-targeting phosphorothioate triple helix-forming oligonucleotide in human leukemia cells.

Authors:  E M McGuffie; D Pacheco; G M Carbone; C V Catapano
Journal:  Cancer Res       Date:  2000-07-15       Impact factor: 12.701

4.  Reversible tumorigenesis by MYC in hematopoietic lineages.

Authors:  D W Felsher; J M Bishop
Journal:  Mol Cell       Date:  1999-08       Impact factor: 17.970

5.  Interaction of actinomycin D with promoter element of c-met and its inhibitory effect on the expression of c-Met.

Authors:  Garima Singhal; Moganty R Rajeswari
Journal:  J Biomol Struct Dyn       Date:  2009-04

Review 6.  Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.

Authors:  Joseph Paul Eder; George F Vande Woude; Scott A Boerner; Patricia M LoRusso
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

7.  Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents.

Authors:  S Fan; J A Wang; R Q Yuan; S Rockwell; J Andres; A Zlatapolskiy; I D Goldberg; E M Rosen
Journal:  Oncogene       Date:  1998-07-16       Impact factor: 9.867

8.  RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis.

Authors:  Riccardo Taulli; Paolo Accornero; Antonia Follenzi; Tony Mangano; Alessandro Morotti; Claudio Scuoppo; Paolo E Forni; Francesca Bersani; Tiziana Crepaldi; Roberto Chiarle; Luigi Naldini; Carola Ponzetto
Journal:  Cancer Gene Ther       Date:  2005-05       Impact factor: 5.987

Review 9.  Hepatocyte growth factor, its receptor, and their potential value in cancer therapies.

Authors:  Wen G Jiang; Tracey A Martin; Christian Parr; Gaynor Davies; Kunio Matsumoto; Toshikazu Nakamura
Journal:  Crit Rev Oncol Hematol       Date:  2005-01       Impact factor: 6.312

10.  The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells.

Authors:  K M Weidner; M Sachs; W Birchmeier
Journal:  J Cell Biol       Date:  1993-04       Impact factor: 10.539

View more
  3 in total

1.  Targeted genome modification via triple helix formation.

Authors:  Adele S Ricciardi; Nicole A McNeer; Kavitha K Anandalingam; W Mark Saltzman; Peter M Glazer
Journal:  Methods Mol Biol       Date:  2014

Review 2.  Liver-targeted gene therapy: Approaches and challenges.

Authors:  Rajagopal N Aravalli; John D Belcher; Clifford J Steer
Journal:  Liver Transpl       Date:  2015-06       Impact factor: 6.112

Review 3.  Non-canonical DNA structures: Diversity and disease association.

Authors:  Aparna Bansal; Shikha Kaushik; Shrikant Kukreti
Journal:  Front Genet       Date:  2022-09-05       Impact factor: 4.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.